Division of Cardiology, Department of Medicine, Einstein Medical Center, Philadelphia, PA 19141, USA.
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28.
Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia.
新型冠状病毒病 2019(COVID-19)迅速演变为全球卫生紧急情况。呼吸道疾病是这些患者发病率和死亡率的主要原因,疾病谱从无症状亚临床感染到严重肺炎进展为急性呼吸窘迫综合征。越来越多的证据描述了 SARS-CoV-2 感染与其他冠状病毒感染(如严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒(MERS-CoV))在病理生理学上的相似性。血管紧张素转换酶 2 受体在病毒发病机制中起关键作用。该受体的破坏可导致心肌病、心功能障碍和心力衰竭。心血管疾病患者更容易感染 SARS-CoV-2,并且更容易出现严重症状。高血压、心律失常、心肌病和冠心病是 COVID-19 重症患者中主要的心血管疾病合并症。越来越多的文献探讨了 SARS-CoV-2 对心脏的影响。心肌损伤是 COVID-19 的重要发病特征之一。作为心肌损伤的替代指标,多项研究表明,感染患者特别是重症患者的心脏生物标志物(主要是心肌肌钙蛋白 I 和 T)升高。心肌炎是 COVID-19 患者发病率的另一个原因。SARS-CoV-2 如何引起心肌损伤的确切机制尚不清楚。心肌损伤的机制包括心肌细胞直接损伤、全身炎症、心肌间质纤维化、干扰素介导的免疫反应、1 型和 2 型辅助 T 细胞过度的细胞因子反应,以及冠状动脉斑块不稳定和缺氧。